Business
Picard / SynCardia Featured on the Cruxx of MedTech Podcast
TUCSON, Ariz., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced the launch of the Cruxx to MedTech Podcast discussing series exploring the SynCardia Total Artificial Heart (STAH) and the next generation, fully implantable Emperor device through the lens of patients and management. Anchor
About this update from Picard Medical, Inc.
[{"type":"image","alt":"Picard Medical, Inc.","displaySize":"","headline":null,"caption":"Picard Medical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/4e25733b249cfcdd029f5354275c291a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gcgpu3t6z4ZWVpSIwIEbWQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4e25733b249cfcdd029f5354275c291a","width":300,"height":75}},"lazy":false},{"type":"text","content":"TUCSON, Ariz., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced the launch of the Cruxx to MedTech Podcast discussing series exploring the SynCardia Total Artificial Heart (STAH) and the next generation, fully implantable Emperor device through the lens of patients and management.","length":493,"tagName":"p"},{"type":"text","content":"Anchored by a powerful patient survival story, the series highlights the real-world impact of the STAH on patients facing end stage heart failure. The discussion then turns to SynCardia System’s / Picard Medical’s CEO, Patrick NJ Schnegelsberg who outlines the Company’s STAH platform and its next generation fully implantable Emperor system. Management highlights the clear differentiation of STAH compared to other approaches, the Company’s long-term vision to create a true alternative to heart transplantation, and the significant commercial opportunity driven by the global shortage of donor hearts.","length":604,"tagName":"p"},{"type":"text","content":"The podcast will be available for download and streaming on all major platforms, including Apple Podcasts, Spotify, and Google Podcasts and available directly on Cruxx’s website here: https://www.thisiscruxx.com/content-hub/","length":224,"tagName":"p"},{"type":"text","content":"About Cruxx","length":11,"tagName":"p"},{"type":"text","content":"Cruxx is a medical technology search and capital advisory firm on a mission to place MedTech pioneers in transformative roles that help people live longer. With a focus on critical fields such as cardiovascular, surgical robotics, neurotechnology, AI, and digital health, Cruxx partner...